Methods of treating HIV-associated neurological disorders (HAND)
View Patent ↗In the present disclosure, doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, were treated with PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) and effects on Tat-induced behavioral impairments and neuropathologies were observed. This disclosure shows that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor, exacerbated Tat neurotoxicity in iTat mice. These findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggest that α7 nAChR and PNU-125096 hold significant promise for development of therapeutics for HAND.
1. A method of treating HIV-associated neurological disorders (HAND) in a subject, wherein the method comprises administering an effective dose of a positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptor, and an integrase inhibitor, wherein the PAM is PNU-120596 (1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea).
2. The method of claim 1 , wherein the effective dose of the PAM of α7 nicotinic acetylcholine receptor comprises about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, or about 1000 mg per day.
3. The method of claim 1 , wherein the effective dose of the PAM of α7 nicotinic acetylcholine receptor comprises about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1.0 mg/kg, about 1.5 mg/kg, about 2.0 mg/kg, about 2.5 mg/kg, about 3.0 mg/kg, about 3.5 mg/kg, about 4.0 mg/kg, about 4.5 mg/kg, about 5.0 mg/kg, about 6.0 mg/kg, about 7.0 mg/kg, about 8.0 mg/kg, about 9.0 mg/kg, about 10 mg/kg about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, or about 50 mg/kg per day.
4. The method of claim 1 , wherein the effective dose of the PAM of α7 nicotinic acetylcholine receptor results in a serum concentration in the subject of about 0.1 μM, about 0.2 μM, about 0.3 μM, about 0.4 μM, about 0.5 μM, about 0.6 μM, about 0.7 μM, about 0.8 μM, about 0.9 μM, about 1.0 μM, about 2.0 μM, about 3.0 μM, about 4.0 μM, about 5.0 μM, about 6.0 μM, about 7.0 μM, about 8.0 μM, about 9.0 μM, or about 10 μM.
5. The method of claim 1 further comprising administering one or more of a nucleotide reverse transcriptase inhibitor (NRTI), a non-nucleotide reverse transcriptase inhibitor (NNRTI), and a protease inhibitor (PI).
6. The method of claim 5 , wherein the nucleotide reverse transcriptase inhibitor (NRTI) is selected from one or more of abacavir, emtricitabine, lamivudine, tenofovir disoproxil fumarate, or zidovudine.
7. The method of claim 5 , wherein the non-nucleotide reverse transcriptase inhibitor (NNRTI) is selected from one or more of doravirine, efavirenz, etravirine, nevirapine, or rilpivirine.
8. The method of claim 5 , wherein the protease inhibitor (PI) is selected from one or more of atazanavir, darunavir, fosamprenavir, ritonavir, saquinavir, or tipranavir.
9. The method of claim 1 , wherein the integrase inhibitor is selected from one or more of dolutegravir, or raltegravir.
10. The method of claim 1 , wherein the method results in improved mood, psychiatric benefits, improved locomotor functions, improved learning, and/or improved memory deficits in the subject.